Clinical trials: Infliximab
Inflammatory Bone Disease
Infliximab Proactive Drug Monitoring in the Pediatric IBD Population
Inflammatory bowel disease (IBD) is a chronic condition that causes inflammation of the intestinal tract. Common types of IBD include Crohn's disease, ulcerative colitis, and indeterminate colitis.
- Trial name
- NCT04921670
- Testing
- Infliximab Assay
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Cares, Kristen, M.D.
Crohn's Disease
Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation
The goal of the present study is to evaluate if addition of methotrexate can restore remission after loss of response to infliximab after dose escalation.
- Trial name
- NCT02269358
- Testing
- METHOTREXATE
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Prof. Arie Levine
Inflammatory Bowel Disease, Crohn's Disease
The Role of Small Bowel Ultrasound in Initiation of Infliximab in Crohn's Disease Patients
Goal is to prospectively determine if stool calprotectin and change in bowel wall thickness and hyperemia, as seen on small bowel ultrasound, at week 0, 14, and 54 can be used to predict response at week 54 to infliximab in…
- Trial name
- NCT02330458
- Testing
- Small bowel ultrasound
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Rheumatoid Arthritis
Safety and Effectiveness of Infliximab in Slovakia When Used for Rheumatoid Arthritis (Study P04741)(COMPLETED)
This study will gather information on the safety and efficacy of patients with rheumatoid arthritis (RA) who are starting treatment with infliximab for the first time.
- Trial name
- NCT00724243
- Testing
- Infliximab
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn Disease, Child, Only
Pharmacokinetic Infliximab Data in Pediatric Crohn's Disease
Rationale: Crohn's disease (CD) is a chronic, debilitating inflammatory bowel disease (IBD) which is diagnosed during childhood in up to one in ten patients.
- Conditions
- Crohn Disease, Child, Only, Biologic; Inadequate
- Trial name
- ProRAPID (NCT05552287)
- Testing
- Infliximab
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Spondylitis
Efficacy and Safety Study of Infliximab (Remicade) to Treat Early Ankylosing Spondylitis
This is a prospective open-label study to evaluated the efficacy and safety of infliximab(Remicade) in treating of patients with early ankylosing spondylitis (AS).
- Trial name
- NCT00936143
- Testing
- infliximab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Gu Jieruo
Crohn Disease
Biomarkers to Predict and Monitor Response to Infliximab
The aim of the study is to generate novel minimally-invasive serum protein signatures and biomarkers in children and adolescents with Crohn's Disease (CD) that correlate with and can predict and monitor patients who will have a…
- Trial name
- NCT04655729
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Massachusetts General Hospital
Crohn's Disease, Ulcerative Colitis
Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.
- Trial name
- NCT03884439
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 428 people
- Sponsor
- Pfizer
Crohn's Disease, Ulcerative Colitis
Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
This study aims to test the hypothesis that the accelerated infusion of infliximab is not inferior to the conventional 2 hour infusion with respect to the frequency of infusion reaction.
- Trial name
- NCT01346826
- Testing
- Standard 2 hours-infusion, Accelerated 1 hour-infusion, Accelerated 30 minutes-infusion
- Where
- South Korea
- Volunteers
- 145 people
- Sponsor
- Asan Medical Center
Hidradenitis Suppurativa
Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa
A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa
- Trial name
- HS2006 (NCT00795574)
- Testing
- infliximab
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Infliximab, Infusion
Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease
OBJECTIVES OF THE STUDY 1. Investigate whether there are just as few infusion reactions with infliximab infusions of 60 min and 30 min. 2. Investigate patient and nurse satisfaction with infusions of 60 min and 30 min. 3.
- Conditions
- Infliximab, Infusion, IBD (Inflammatory Bowel Disease), Patient Satisfaction
- Trial name
- iRAPID (NCT06839820)
- Testing
- Infusion rate of infliximab
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- University Hospital, Akershus
Rheumatoid Arthritis
Infliximab for the Treatment of Early Rheumatoid Arthritis
This study will test whether the drug combination of methotrexate and infliximab (anti-TNF-alpha antibody) is more effective than methotrexate alone for treating rheumatoid arthritis early in the disease.
- Trial name
- NCT00006292
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Crohn's Disease
Infliximab Top-down in Pediatric Crohn
The purpose of this study is to determine whether a top-down treatment approach, prescribing infliximab and azathioprine at diagnose, yields better outcome in comparison to the usual step-up treatment approach, starting with…
- Trial name
- ITSKids (NCT01880307)
- Testing
- Azathioprine, Infliximab, Prednisolon
- Where
- 2 sites in Italy, Netherlands
- Volunteers
- 13 people
- Sponsor
- Erasmus Medical Center
Arthritis, Rheumatoid, Colitis, Ulcerative
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
The purpose of this study is to learn about the safety of the safety of the study medicine called infliximab for the possible treatment of rheumatoid arthritis (RA), ulcerative colitis (UC, Crohn's disease, or psoriasis.
- Conditions
- Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis
- Trial name
- NCT05796245
- Where
- Japan
- Volunteers
- 2,207 people
- Sponsor
- Pfizer
Crohn Disease
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
The main purpose of this study is to record the use of Infliximab (IFX) in the treatment of Chinese children with Crohn's disease (CD) in routine clinical practice and to summarize the clinical efficacy and safety of IFX in the…
- Trial name
- NCT04312659
- Testing
- Infliximab
- Where
- 5 sites in China
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson (China) Investment Ltd.
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Arthritis, Rheumatoid, Crohn Disease
A Long-term Safety Study of Infliximab (Remicade)
This is a study evaluating the long-term safety of infliximab (Remicade)
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Trial name
- NCT00261976
- Testing
- Infliximab (Remicade)
- Where
- 205 sites in United States, Argentina and 17 more
- Volunteers
- 2,971 people
- Sponsor
- Centocor, Inc.
Ulcerative Colitis
CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis
The primary endpoint will be evaluated through the following variables: PUCAI score, IFX levels, and steroid treatment. Clinical response to IFX will be evaluated through the PUCAI score.
- Trial name
- NCT05430412
- Testing
- Adacolumn
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 15 people
- Sponsor
- Adacyte Therapeutics SL
Pediatric Inflammatory Bowel Disease
Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience
There is little data published on the long term durability of infliximab in pediatric patients. In particular a focus on durable remission, frequency of dose/frequency change and switch within class.
- Trial name
- NCT01490528
- Volunteers
- 200 people
- Sponsor
- Cedars-Sinai Medical Center
Inflammatory Bowel Disease, Crohn's Disease
IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study
Crohn's disease (CD) is a lifelong condition of inflammation in the bowel. CD can affect any part of the gastrointestinal tract from mouth to anus.
- Trial name
- IDeaL (NCT02847884)
- Testing
- Infliximab
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- University of Alberta